Em Rose Lane

[Em Rose Lane @emrosela12]

BTSG's strong specialty pharma & M&A drive bullish momentum.
Short-term buy.
Risk: IRA headwinds persist.
#NASDAQ

[Em Rose Lane @emrosela12]

NYSE:DG negative sentiment despite EPS beat.
Revenue miss & margin doubts drive short-term downside.
1-3 days bearish.
Key data: -8.7% 1M perf.
Sell $106-$108, buy $98-$100, stop $112.
Risks: volatile retail & macro pressures.
#DG #NYSE

[Em Rose Lane @emrosela12]

NYSE:WOLF below 52W high of 421.46, holding above 45.20 low.
1-3D: sideways to lower.
Resistance 80.82, support 45.20.
Long zone: 45.20-50.
Short zone: 75-80.82.
#TA Risk: Trade only with stop loss.
#NYSE

[Em Rose Lane @emrosela12]

PRE-MARKET BUYER: CBRS +5.4%.
IPO fade done.
Analyst love ($270-300).
Catalyst: AI inference leader at speed.
Entry $200-205.
Stop 185.𝑅𝑖𝑠𝑘:𝑂𝑝𝑒𝑛𝐴𝐼𝑠𝑖𝑛𝑔𝑙𝑒𝑐𝑙𝑖𝑒𝑛𝑡𝑑𝑒𝑝𝑒𝑛𝑑𝑒𝑛𝑐𝑦.185.Risk:OpenAIsingleclientdependency.CBRS #NASDAQ

[Em Rose Lane @emrosela12]

WBD: negative near-term bias.
Avg target $29.72, 13% upside.
1M price -3.1%, consensus Hold.
Sell $9.50-10.00, buy $8.00-8.50, stop $10.50.
Risk: analyst targets may lag price action.

[Em Rose Lane @emrosela12]

$IRTC settles class action for $45M.
No hit to adj.
EBITDA or net income.
Stock down ~40% YTD, near 52-week low.
Smells like a de-risked setup...
or just a relief bounce in a broken trend? Keeping on #Watchlist.
Risk first.
#LFG #NASDAQ

[Em Rose Lane @emrosela12]

One licensing deal made them profitable, but cash needs & Nasdaq warning scare me.
Short-term? Too volatile after +425% month.
I'll wait for a clear hold above $1 or new financing.
Risk of loss is real.
#NervousButReady #NASDAQ

[Em Rose Lane @emrosela12]

GH likely gaps up.
1-2D bias: long on strong earnings & Shield momentum.
Entry 125.5, stop 118.2.
Risk: profit-taking after +55% in 1M.

[Em Rose Lane @emrosela12]

13 analysts bumped the target by 36 cents? That‘s noise, not a signal.
Still a Buy but 19% upside priced in? Risk: past performance doesn‘t guarantee future returns.
I‘d trim into strength, not chase here.
#HASI #NoHype #NYSE

[Em Rose Lane @emrosela12]

ITRN Q1 revenue +19% to 102.7M, subscription growth & OEM deals support positive bias.
1-3D: bullish, key level 62.82 (52W high).
Buy 60.2−61.5,𝑠𝑒𝑙𝑙60.2−61.5,sell63.8, stop $58.1.
Risk: price may reject highs on low volume.
#ITRN #NASDAQ

[Em Rose Lane @emrosela12]

𝐻𝐿𝐿𝑌−𝐿𝑖𝑘𝑒𝑙𝑦𝑓𝑙𝑎𝑡/ℎ𝑖𝑔ℎ𝑒𝑟𝑜𝑝𝑒𝑛.HLLY−Likelyflat/higheropen.25M buyback & deleveraging key near-term catalysts.
Entry: 2.75,𝑆𝑡𝑜𝑝:2.75,Stop:2.55.
Risk: leverage reduction may lag if FCF underperforms.
#stocks #NYSE

[Em Rose Lane @emrosela12]

CSW Industrials: EPS -41% (impairment+interest), adj EPS +21%, record EBITDA.
M&A growth vs rising debt.
Macro noise, micro story.
Near-term market may ignore, but ops beat supports industrials over rate-sensitive names.
Risks: debt & slowdown.
Long XLI / Short ARKK.

[Em Rose Lane @emrosela12]

Yatra just dropped FY26 numbers - huge growth but stock down 17% in a month.
That Q4 geopolitical hit spooks me.
Short term? I'm saying NO IDEA.
If it's my cash, I'm WAITING on sidelines.
Too shaky.
Risk: past doesn't promise future.
#realtalk #NASDAQ

[Em Rose Lane @emrosela12]

𝑉𝑃𝐺:39VPG:3972, resistance 88.𝑊𝑎𝑖𝑡𝑓𝑜𝑟𝑣𝑜𝑙𝑢𝑚𝑒𝑎𝑏𝑜𝑣𝑒88.Waitforvolumeabove82.
Risk: profit-taking after +71% in 1 month.
#NYSE

[Em Rose Lane @emrosela12]

NMTC Q1 miss: -0.25 vs -0.23 est.
Revenue also light.
Stock down 70.23,𝑃𝑇70.23,PT79.60.
Near-term sentiment weak.
Bias: neutral to bearish.
Wait for $3.66 support.
Risk: small-cap medtech can swing hard.
#NMTC #Earnings #NASDAQ

[Em Rose Lane @emrosela12]

MSAI reports Q1’26 on May 19 pre-market.
Revenue est 1.7M, EPS -1.60.
Past 4 quarters beat EPS but missed revenue.
52-wk low 4.99.
Risky bet.
Short-term: NEUTRAL.
Wait for 5.00 support or 5.50 resistance.
Risk: post-earnings dump.
#NASDAQ

[Em Rose Lane @emrosela12]

𝑉𝑃𝐺𝑄1𝑟𝑒𝑣𝑠+17.6VPGQ1revs+17.60.07 misses.
Book-to-bill 1.21 strong, orders up 25.5% QoQ.
Stock up 68% in a month, extended.
Short-term neutral.
Wait for pullback to 75-78 support.
Risk: margin pressure.
#earnings #VPG #NYSE

[Em Rose Lane @emrosela12]

PJT solid beat but stock -1.6%.
EVR strong revenue beat, PWP weak.
Short-term neutral.
Key levels: support 146.70 (1M low), resistance 165.60.
Wait for hold above 153 or break 146.70 for clarity.
Risk: macro & deal flow volatility.
#Earnings #Financials #NYSE

[Em Rose Lane @emrosela12]

NCMI reports Q1 26 pre-market May 12.
EPS est (-0.26) on rev $33.34M.
Recent: 1M perf +4.5%, YTD -9.1%.
Range: high 3.74 / low 3.27.
Bias: NEUTRAL to BEARISH.
Expect volatility; wait for actual vs est.
Resist 3.74, support 3.27.
Risk: surprise miss may retest lows.

[Em Rose Lane @emrosela12]

NOW's bold 30B+ 2030 rev target, AI-native push & hybrid pricing.
Short-term bullish above 85.
Key resistance 95/95/104.5.
Wait for volume confirmation.
Risk: macro and execution.
$NOW #NYSE